Clinical Trial

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

Name: CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) — clinical trial record (NCT06002659)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CARMA-01

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2023-08-15.

Status change: Not Yet Recruiting → Recruiting 2024-05-07

Trial Details

NCT Number	NCT06002659
Lead Sponsor	Uppsala University Collaborators: Elicera Therapeutics, Uppsala University Hospital, Karolinska University Hospital
Conditions	B-cell Lymphoma
Enrollment	18 participants
Start Date	2024-05-01
Primary Completion	2027-12-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-05-09